Detalhe da pesquisa
1.
Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy.
Clin Infect Dis
; 70(12): 2599-2606, 2020 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31595301
2.
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.
Clin Infect Dis
; 68(4): 597-606, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29912307
3.
Latent tuberculosis infection screening and treatment in HIV: insights from evaluation of UK practice.
Thorax
; 72(2): 180-182, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27742873
4.
HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK.
J Antimicrob Chemother
; 71(12): 3487-3494, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27856703
5.
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Lancet
; 382(9893): 700-8, 2013 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-23830355
6.
Has the time come to abandon efavirenz for first-line antiretroviral therapy?
J Antimicrob Chemother
; 69(7): 1742-7, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24603962
7.
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
Nat Med
; 11(11): 1170-2, 2005 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16205738
8.
Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.
Dermatol Ther (Heidelb)
; 12(5): 1073-1089, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35445963
9.
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.
BMC Infect Dis
; 11: 23, 2011 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-21266068
10.
FLAMINGO: how much rosier can antiretroviral therapy get?
Lancet
; 383(9936): 2191-3, 2014 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-24698484
11.
Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14â894 patients across 14 trials.
AIDS
; 34(15): 2259-2268, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33048869
12.
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
N Engl J Med
; 354(3): 251-60, 2006 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-16421366
13.
More pressure on integrase strand-transfer inhibitors?
Lancet HIV
; 11(5): e278-e280, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38621391
14.
Global access of rifabutin for the treatment of tuberculosis - why should we prioritize this?
J Int AIDS Soc
; 22(7): e25333, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31318176
15.
Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects.
J Int AIDS Soc
; 22(7): e25352, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31298496
16.
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
AIDS
; 33(9): 1455-1465, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30932951
17.
Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
Antivir Ther
; 13(5): 655-61, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18771049
18.
Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing.
J Antimicrob Chemother
; 62(1): 161-7, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-18467305
19.
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.
J Antimicrob Chemother
; 62(6): 1344-55, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18824460
20.
A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
Br J Clin Pharmacol
; 65 Suppl 1: 54-9, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18333866